Most women with breast cancer patients in stages I to III treated with chemotherapy, hormone therapy, and HER2-targeted drugs, such as trastuzumab (Herceptin) and pertuzumab (Perjeta), followed by surgery and radiotherapy. This evidence concerns the gene ERBB2 and breast cancer.